Osteoporosis secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 9: | Line 9: | ||
==Secondary prevention== | ==Secondary prevention== | ||
===Medication=== | ===Medication=== | ||
* Just as for treatment, [[bisphosphonate]]<ref name="pmid22805729">{{cite journal |author=Zhang J, Wang R, Zhao YL, ''et al.'' |title=Efficacy of intravenous zoledronic acid in the prevention and treatment of osteoporosis: A meta-analysis |journal=Asian Pac J Trop Med |volume=5 |issue=9 |pages=743–8 |year=2012 |month=September |pmid=22805729 |doi=10.1016/S1995-7645(12)60118-7 |url=}}</ref> can be used in cases of very high risk. Other medicines prescribed for prevention of osteoporosis include [[raloxifene]] (Evista), a [[selective estrogen receptor modulator]] (SERM). | * Just as for treatment, [[bisphosphonate]]<ref name="pmid22805729">{{cite journal |author=Zhang J, Wang R, Zhao YL, ''et al.'' |title=Efficacy of intravenous zoledronic acid in the prevention and treatment of osteoporosis: A meta-analysis |journal=Asian Pac J Trop Med |volume=5 |issue=9 |pages=743–8 |year=2012 |month=September |pmid=22805729 |doi=10.1016/S1995-7645(12)60118-7 |url=}}</ref> can be used in cases of very high risk. Other medicines prescribed for prevention of osteoporosis include [[raloxifene]]<ref name="pmid22405286">{{cite journal |author=Dadiboyena S |title=Recent advances in the synthesis of raloxifene: a selective estrogen receptor modulator |journal=Eur J Med Chem |volume=51 |issue= |pages=17–34 |year=2012 |month=May |pmid=22405286 |doi=10.1016/j.ejmech.2012.02.021 |url=}}</ref> (Evista), a [[selective estrogen receptor modulator]] (SERM). | ||
* Estrogen replacement remains a good treatment for prevention of osteoporosis but, at this time, is not recommended unless there are other indications for its use as well. There is uncertainty and controversy about whether estrogen should be recommended in women in the first decade after the menopause; hopefully new research will provide guidance. In men, testosterone replacement therapy is also an effective treatment. | * Estrogen replacement remains a good treatment for prevention of osteoporosis but, at this time, is not recommended unless there are other indications for its use as well. There is uncertainty and controversy about whether estrogen should be recommended in women in the first decade after the menopause; hopefully new research will provide guidance. In men, testosterone replacement therapy is also an effective treatment. | ||
Revision as of 19:04, 22 July 2012
Osteoporosis Microchapters |
Diagnosis |
---|
Treatment |
Medical Therapy |
Case Studies |
Osteoporosis secondary prevention On the Web |
American Roentgen Ray Society Images of Osteoporosis secondary prevention |
Risk calculators and risk factors for Osteoporosis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2], Raviteja Guddeti, M.B.B.S.[3]
Overview
Secondary prevention involves use of medications, based on the earliest possible identification of disease so that it can be more readily treated or managed and adverse sequelae can be prevented.
Secondary prevention
Medication
- Just as for treatment, bisphosphonate[1] can be used in cases of very high risk. Other medicines prescribed for prevention of osteoporosis include raloxifene[2] (Evista), a selective estrogen receptor modulator (SERM).
- Estrogen replacement remains a good treatment for prevention of osteoporosis but, at this time, is not recommended unless there are other indications for its use as well. There is uncertainty and controversy about whether estrogen should be recommended in women in the first decade after the menopause; hopefully new research will provide guidance. In men, testosterone replacement therapy is also an effective treatment.
References
- ↑ Zhang J, Wang R, Zhao YL; et al. (2012). "Efficacy of intravenous zoledronic acid in the prevention and treatment of osteoporosis: A meta-analysis". Asian Pac J Trop Med. 5 (9): 743–8. doi:10.1016/S1995-7645(12)60118-7. PMID 22805729. Unknown parameter
|month=
ignored (help) - ↑ Dadiboyena S (2012). "Recent advances in the synthesis of raloxifene: a selective estrogen receptor modulator". Eur J Med Chem. 51: 17–34. doi:10.1016/j.ejmech.2012.02.021. PMID 22405286. Unknown parameter
|month=
ignored (help)